Investing.com | Sep 22, 2020 11:24
For most market sectors, a company’s earnings report enables investors to assess its performance and measure of how management has done. And for that reason, these reports are awaited with great anticipation.
When the Edmonton-based company posts its results after the closing bell later today, the information will be used to assess just how well the company managed expectations. That alone is what investors will be reacting to.
The main financial headlines about the marijuana grower’s fourth quarter results are already known, even though they have yet to be officially reported. This is one way to avoid the shock of bad news—break it gently to investors.
The results were essentially revealed a few weeks ago when the company announced its new CEO, Miguel Martin. Aurora used the occasion to share news it would also be taking a C$1.8 billion (US$1.368 billion) write-down. This is in addition to a previous $1 billion write-down it had taken earlier in the year.
The only metric still awaited with anticipation will be sales growth. But from a strategic point of view, investors are eager to learn any details about Aurora's plan to push further into the U.S. market. This is where the company holds onto hope that it will be able to turn its numbers around.
As other Canadian-based cannabis companies have looked to boost revenues in the derivative markets—what is commonly referred to as the 2.0 products—Aurora has opted to focus its attention on U.S. markets. How quickly it can turn that strategy into sales is not entirely clear.
Florida-based cannabis company Trulieve Cannabis (OTC:TCNNF), (CSE:TRUL) last week announced it is going to expand its footprint in the U.S., with the purchase of two marijuana companies in Pennsylvania: PurePenn and Solevo Wellness.
The deal for PurePenn, a grower and processor of medical marijuana licensed by the Pennsylvania Department of Health, includes a payment of US$46 million—US$27 million in Trulieve stock and US$19 million in cash, with potentially an additional US$60 million if certain financial targets are hit.
Trulieve has agreed to pay US$20 million for Solevo, which operates three medical marijuana dispensaries in Pittsburgh, split equally in cash and shares, with a possible additional payment of $15 million upon hitting agreed to financial benchmarks.
While shares of Trulieve have dropped about 11% since the deal was announced, their value has increased more than 110% in the last year.
For business marketing highs, the legal marijuana trade has not produced too many in the past year. In the absence of positive news, analysts have been looking for the next best thing – signs of good news. Even in this category, one Canadian-based cannabis grower continues to disappoint—Hexo (NYSE:HEXO), (TSX:HEXO).
Yesterday, shares of the Ottawa-based cannabis corporation closed down just over 8%, as it continues to struggle to find footing. Hoping to send an uplifting signal last week, HEXO announced the appointment of a new chief financial officer.
But the move fell flat as analysts were unimpressed. One reason: it's the company’s fourth CFO to be named in the last year.
The new CFO is Trent MacDonald, a former executive with pharmacy chain Rx Drug Mart, Canadian book retailer Indigo (TSX:IDG) and grocery chain Sobeys.
Another reason the news failed to impress was outlined by Jefferies analyst Owen Bennett, who pointed to MacDonald’s lack of experience in the global consumer goods space. As Bennett said, the choice does not inspire confidence.
In the last year, Hexo shares have lost more than 80% of their value.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Get free real time quotes, charts and alerts on stocks, indices, currencies, commodities and bonds. Get free top of the line technical analysis/predictors.
More content, faster quotes and charts, and a smoother experience is available only on the App.